Hepatitis A and hepatitis E, which are transmitted via the fecal-oral route are still endemic in many countries. HAV and HEV usually cause self-limiting hepatitis, but particularly HEV may have a serious impact on immunosuppressed patients and they can become chronically infected with the possible serious outcome. HCV infection is thought to be well treated and controlled thanks to extremely effective and safe treatments. Nevertheless, the elimination and achievement of WHO goals for 2030 are more than problematic. Strategies on the country level are essential. So far eradication of HBV infection cannot be achieved because of cccDNA presence in hepatocytes, but new treatments are in clinical trials. Altogether, there are many unresolved issues but extensive research on this topic may change future scenarios in the world of viral hepatitis.
The goal of this Research Topic is to explore recent achievements, research ideas, and strategies to achieve a world free of viral hepatitis as a public health problem. Having effective vaccines against HAV and HBV and curative treatments of HCV infection and suppressive therapies in HBV, viral hepatitis is still a challenge and is responsible for extensive mortality and morbidity. Hope contributors of this topic will present solutions of unresolved issues, including public health, diagnostic and therapeutic aspect of viral hepatitis. The role of both scientific background and experience for clinical practice is a must to achieve success.
The scope of this Research Topic includes all aspects of viral hepatitis, particularly epidemiology and screening strategies, the impact of COVID-19 pandemic on the process of WHO elimination plan, new diagnostic tools, including liver fibrosis assessment and screening for hepatocellular carcinoma, the coincidence of liver pathology of various origin, new therapeutics, vaccine development.
Original manuscripts are preferred, however, all types of manuscripts might be considered. Case reports will not be accepted, but a series of cases with extremely important interests might be considered.
Hepatitis A and hepatitis E, which are transmitted via the fecal-oral route are still endemic in many countries. HAV and HEV usually cause self-limiting hepatitis, but particularly HEV may have a serious impact on immunosuppressed patients and they can become chronically infected with the possible serious outcome. HCV infection is thought to be well treated and controlled thanks to extremely effective and safe treatments. Nevertheless, the elimination and achievement of WHO goals for 2030 are more than problematic. Strategies on the country level are essential. So far eradication of HBV infection cannot be achieved because of cccDNA presence in hepatocytes, but new treatments are in clinical trials. Altogether, there are many unresolved issues but extensive research on this topic may change future scenarios in the world of viral hepatitis.
The goal of this Research Topic is to explore recent achievements, research ideas, and strategies to achieve a world free of viral hepatitis as a public health problem. Having effective vaccines against HAV and HBV and curative treatments of HCV infection and suppressive therapies in HBV, viral hepatitis is still a challenge and is responsible for extensive mortality and morbidity. Hope contributors of this topic will present solutions of unresolved issues, including public health, diagnostic and therapeutic aspect of viral hepatitis. The role of both scientific background and experience for clinical practice is a must to achieve success.
The scope of this Research Topic includes all aspects of viral hepatitis, particularly epidemiology and screening strategies, the impact of COVID-19 pandemic on the process of WHO elimination plan, new diagnostic tools, including liver fibrosis assessment and screening for hepatocellular carcinoma, the coincidence of liver pathology of various origin, new therapeutics, vaccine development.
Original manuscripts are preferred, however, all types of manuscripts might be considered. Case reports will not be accepted, but a series of cases with extremely important interests might be considered.